Oral cancer can develop with few obvious symptoms in its earliest stages, which is why timely detection is so important. Studies consistently show that the earlier a lesion is identified and treated, the greater the chances for successful outcomes and long-term survival. Regular screenings give patients the best opportunity to catch suspicious changes before they progress to more advanced disease.
Certain behaviors and medical factors raise the likelihood of developing oral cancer, including tobacco use, heavy alcohol consumption, prolonged sun exposure to the lips, and persistent human papillomavirus (HPV) infection. Age and a history of prior head or neck cancers also increase risk. Understanding these risk factors helps clinicians prioritize screening and tailor follow-up care for patients who need it most.
Routine oral exams remain the foundation of early detection, but technology can strengthen that foundation. When a screening program combines clinical knowledge with modern diagnostic tools, patients receive a more thorough evaluation—one that improves the odds of finding concerning tissue while it can still be treated effectively.
VELscope® is a handheld diagnostic device that uses a specific blue light to reveal natural tissue fluorescence in the mouth. Healthy oral tissues reflect this light in characteristic ways, while tissue with abnormal cellular changes often shows altered or diminished fluorescence. That visual difference can make subtle lesions stand out against surrounding healthy tissue, helping clinicians identify areas that may warrant closer inspection.
It’s important to emphasize that VELscope® is an adjunctive tool—not a standalone diagnostic test. A conventional visual inspection and careful palpation remain essential. VELscope® simply provides additional information that can guide clinical decision-making, helping clinicians decide whether observation, closer monitoring, or further diagnostic testing is appropriate.
Because VELscope® enhances contrast between normal and abnormal tissue, it can help detect changes that are difficult to see with regular white light alone. For patients who have risk factors or who notice persistent sores, red or white patches, or unexplained lumps, VELscope® screening offers a clear, noninvasive way to supplement the routine exam.
A VELscope® examination is simple, quick, and comfortable for most patients. The clinician will dim the room lights and ask the patient to open wide while the device is passed a few inches from the oral cavity. The procedure usually takes only a couple of minutes and is performed during a regular checkup or hygiene visit, so there’s no separate appointment required in most cases.
The bright blue light is harmless and does not produce heat; patients may experience only mild sensitivity to the light if they are particularly light-sensitive. Because the process is noninvasive, there is no need for injections or tissue removal during the screening itself. The clinician observes the fluorescence pattern and takes note of any irregular areas that appear darker or different from surrounding mucosa.
If an area looks suspicious under the VELscope® examination, the clinician will explain what was seen, document the findings, and discuss the most appropriate next steps. That might include closer clinical monitoring, photographic records for comparison at future visits, or a referral for biopsy when clinical suspicion warrants definitive tissue diagnosis.
An abnormal fluorescence pattern does not automatically mean cancer. Various benign conditions—such as trauma, inflammation, or benign lesions—can also alter tissue fluorescence. Interpreting VELscope® findings requires clinical experience and correlation with the patient’s history, symptoms, and a thorough oral exam.
When the clinician identifies an area of concern, they will outline a clear plan: observe and recheck at a defined interval, obtain a biopsy for definitive diagnosis, or coordinate care with a specialist when appropriate. Documentation, photographic comparison, and consistent follow-up are key components of a responsible screening program and help ensure that any changes are caught and addressed promptly.
For patients, the most important takeaways are to report persistent oral symptoms—such as sores that do not heal, unexplained lumps, numbness, or changes in speech—and to keep scheduled dental visits. Timely communication between patient and clinician is central to effective surveillance and early intervention when necessary.
At the office of Judy Mejido, DMD, PA, VELscope® screening is integrated into a comprehensive preventive care strategy rather than used in isolation. We combine a careful clinical exam with patient education, risk assessment, and appropriate documentation to ensure each patient receives an individualized plan. Our goal is to offer reassurance when findings are benign and to act decisively when further investigation is required.
Clinical competence and ongoing training are essential for accurate interpretation of adjunctive technologies. Our clinical team follows evidence-based protocols and maintains competency through continuing education so that VELscope® findings are evaluated within the broader context of each patient’s overall oral health.
We also believe in empowering patients with practical prevention and early-detection steps: avoiding tobacco products, limiting alcohol, protecting lips from excessive sun exposure, practicing good oral hygiene, and attending regular dental appointments. These measures, together with attentive screening, form the best defense against late-stage disease.
To learn more about how VELscope® screening is used in our office and whether it may be appropriate for you, please contact us for more information.
VELscope cancer screening is an adjunctive, chairside exam that uses a specific blue light to reveal natural tissue fluorescence in the mouth. Healthy oral tissues fluoresce in predictable patterns while areas with altered cellular activity often appear darker or show a different fluorescence pattern. The device is designed to make subtle mucosal changes more visible so clinicians can identify areas that merit closer inspection. VELscope screening is intended to supplement, not replace, a thorough clinical oral exam and medical history review.
The test itself is noninvasive and typically completed in a few minutes as part of a routine dental visit. It does not provide a definitive diagnosis of cancer but helps guide clinical decision-making by highlighting suspicious areas. When used alongside a conventional exam, VELscope can improve the clinician’s ability to monitor and document changes over time. Patients benefit from the added visual information when assessing symptoms or risk factors for oral cancer.
VELscope emits a concentrated blue light that causes oral tissues to produce natural fluorescence. Normal mucosa and submucosal structures reflect that light in characteristic ways, while tissue with dysplasia, inflammation, or other alterations often displays diminished or altered fluorescence. The visual contrast created by the device can make small or flat lesions easier to see than under conventional white light. Clinicians interpret these fluorescence patterns in the context of their clinical exam and patient history.
Because fluorescence can be affected by multiple factors, interpretation requires training and experience to distinguish suspicious findings from benign changes. Photographic documentation is often used to compare fluorescence patterns over time, which helps track progression or resolution. VELscope’s role is to enhance visual assessment rather than to provide histologic information. Any definitive diagnosis relies on clinical correlation and, if indicated, biopsy and laboratory analysis.
VELscope screening may be especially helpful for patients who have known risk factors for oral cancer, such as tobacco use, heavy alcohol consumption, prolonged sun exposure to the lips, or persistent HPV infection. It can also be useful for patients with a history of head and neck cancer or those who report persistent oral symptoms like nonhealing sores, unexplained lumps, numbness, or changes in speech. That said, many practices offer VELscope as part of routine preventive visits because early detection benefits a broad range of patients.
Clinicians use risk assessment and patient history to determine how frequently adjunctive screening is appropriate. For patients without specific risk factors, VELscope can still provide reassurance and a useful baseline image. For higher-risk patients, the device may be used more frequently to monitor suspicious areas. Ultimately, the decision is individualized and made in partnership between patient and clinician.
A VELscope screening at the office of Judy Mejido, DMD, PA is quick, simple, and typically performed during a routine checkup or hygiene appointment. The clinician will dim the lights and inspect the mouth using the handheld device, asking you to open wide so the blue light can illuminate the oral tissues. The procedure is noninvasive, requires no injections, and usually takes only a couple of minutes to complete.
During the exam the clinician will note fluorescence patterns and may take photographs to document findings for future comparison. If an area appears abnormal, the clinician will discuss the observation, explain possible causes, and outline recommended next steps such as closer monitoring, additional imaging, or referral for biopsy. The goal of the visit is to provide clear information and a defined plan for follow-up when necessary.
VELscope screening is generally comfortable and well tolerated by most patients because it is noninvasive and does not emit heat. The blue light itself may cause mild sensitivity in people who are particularly light-sensitive, but this is uncommon and typically brief. No medications, injections, or tissue removal are required during the screening procedure.
There are no known long-term risks associated with the brief light exposure used in VELscope exams. The main limitation is interpretive: benign conditions such as inflammation, trauma, or benign lesions can alter fluorescence and mimic concerning changes. That is why clinical correlation, documentation, and appropriate follow-up are essential components of a safe and responsible screening program.
VELscope enhances the clinician’s ability to detect areas of altered tissue fluorescence, but it is not a diagnostic test and does not distinguish cancer from benign conditions on its own. Studies show the device can increase visibility of suspicious lesions, yet it may also produce false positives when inflammation or trauma affects fluorescence. Clinical experience and correlation with the patient’s history and examination findings are necessary to interpret results correctly.
Because of these limitations, VELscope findings are used to guide next steps—such as closer monitoring, photographic follow-up, or referral for biopsy—rather than to make a definitive diagnosis. The value of VELscope lies in its role as part of a comprehensive screening strategy that includes a physical exam, risk assessment, and, when indicated, histologic evaluation. Patients should view VELscope as one tool among many for early detection and surveillance.
An abnormal fluorescence pattern under VELscope does not automatically indicate cancer, but it does prompt further evaluation. The clinician will explain the observation, document the finding with notes and often photographs, and assess whether the change is consistent with trauma, inflammation, or another benign cause. A plan will be proposed that may include short-term recheck, enhanced monitoring, or referral for diagnostic testing.
If clinical suspicion remains after correlation with history and exam, the clinician may recommend a biopsy to obtain tissue for definitive diagnosis. Coordination with oral medicine specialists or an oral surgeon can be part of that process when specialized assessment or treatment is needed. Clear documentation and timely follow-up are central to ensuring that any significant changes are managed promptly and appropriately.
Screening frequency depends on individual risk factors, clinical findings, and the clinician’s judgment rather than a one-size-fits-all schedule. Patients with significant risk factors or prior abnormal findings may be monitored more frequently, while low-risk patients often receive adjunctive screening as part of their regular dental checkups. Your dental team will consider your history, habits, and any symptoms when recommending an appropriate interval.
Consistency and documentation are key: establishing baseline images and comparing fluorescence patterns over time improves the ability to detect meaningful changes. If a new symptom appears between scheduled visits—such as a persistent sore, lump, numbness, or difficulty speaking—contact your dental provider promptly for evaluation. Timely communication and adherence to recommended follow-up help maximize the benefit of any screening program.
VELscope enhances a routine oral exam by improving the visual contrast between healthy and potentially abnormal tissues, making flat or subtle lesions easier to detect. A conventional exam with careful inspection and palpation remains the foundation of early detection, and VELscope adds additional information that can guide clinical decisions. The combined approach helps clinicians prioritize areas for documentation, monitoring, or biopsy.
Using VELscope alongside clinical judgment, risk assessment, and photographic records strengthens a screening program and supports more informed patient conversations. It provides a noninvasive method to track changes over time and can increase confidence when deciding between observation and further diagnostic steps. Ultimately, the tool complements rather than replaces established diagnostic methods.
Determining whether VELscope screening is appropriate begins with a comprehensive review of your medical history, lifestyle risk factors, and any oral symptoms you may be experiencing. The clinician will discuss factors such as tobacco and alcohol use, sun exposure to the lips, HPV risk, and previous head or neck cancers to assess your baseline risk. That information is combined with a conventional oral exam to decide if adjunctive fluorescence screening will add value.
At the office of Judy Mejido, DMD, PA, patients receive individualized recommendations based on that assessment and the clinician’s experience. If VELscope screening is performed, the results will be documented and explained with clear next steps for monitoring or referral when indicated. The goal is to provide thorough, evidence-informed care that balances early detection with prudent interpretation and follow-up.
Ready to schedule your next dental appointment or have questions about our services?
Contacting Judy Mejido, DMD, PA is easy! Our friendly staff is available to assist you with scheduling appointments, answering inquiries about treatment options, and addressing any concerns you may have. Whether you prefer to give us a call, send us an email, or fill out our convenient online contact form, we're here to help. Don't wait to take the first step towards achieving the smile of your dreams – reach out to us today and discover the difference personalized dental care can make.
